InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [2] - The company was founded in 2007 and has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA [3] Product Development - InflaRx's lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling, which has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies [2] - The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa [2] - InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies [2] Upcoming Events - InflaRx will participate in the Leerink Partners Global Healthcare Conference from March 8 to 11, 2026, in Miami, FL, with a fireside chat scheduled for March 9 at 9:20 AM ET [1]